Colorectal cancer (CRC) is the third most commonly occurring cancer globally regardless of sex. In the year 2016, the United States solely had 134, 490 new CRC cases (NCI, 2016). Recent reports have shown that there is an increase in CRC incidence in young population in many resource-constrained countries including India 1 and the 5-year survival rate in India is below 40%, which is one of the lowest compared to western countries. 2 CRC treatment and management have indeed evolved over a couple of decades due to improved screening and therapeutic modalities. This paradigm shift in CRC regimen has been possible because of extensive knowledge about the pivotal molecular players and pathways involved in the disease, which has finally aided in augmentation of potent anti-tumour therapeutics. Despite these significant developments, disease relapse and distant metastasis remain as major challenges in CRC. Patients with distal margin enriched for CD133 expression showed an increased recurrence rate and decreased disease-free survival. This study proposes that although distal margin seems to be tumour free in conventional histopathological analysis, it could harbour cells enriched for CSC markers. Further CD133 could be a promising molecule to be used in molecular pathology for disease prognosis after surgery in CRC patients.
It is known that around 20% to 40% of patients undergoing curative resection for CRC develop loco-regional recurrence or distant metastasis. 4 Although chemoradiotherapy has radically enhanced the treatment efficacy in CRC, still surgery remains the conclusive treatment regimen given to most patients. Removal of all residual cells in and around tumour has been suggestive of an effective surgery. In CRC, excision of surgical margins along with tumour is critical for curative surgery practice, as studies have shown that positive surgical margins correlate with disease recurrence and distant metastasis. 5, 6 Presently, biopsies are evaluated visually by microscopic examination of hematoxylin and eosin stained slides by a pathologist. However, molecular alterations and residual tumour cells may go unnoticed in conventional pathology. Molecular evaluation of surgical margins has been described to be more sensitive and informative compared to conventional histopathological assessment in many cancers. 7 Currently, insights on molecular signatures of surgical margins are lacking, which otherwise could aid in defining tumour-free resectable margin in CRC. Criteria for precise selection of distal margin in a sphincter preserving surgery need more research as distal resection length still remains a topic of debate. 8 Molecular assessment includes many advanced and precise techniques, which enable to assess many risk parameters and could be of help in improved prognosis of patients.
Presently, there is a need for robust, reliable prognostic and predictive molecular markers in CRC, which could help oncologist to decide patient-specific treatment regimens as well as help in better patient's follow-up post surgery. Accumulating evidence on a sub-population of cells in tumours, demonstrated to have high tumourigenic proficiency compared to the bulk of the tumour cells and were designated as cancer stem cells (CSCs). CSCs are reported to be the possible culprits behind therapy resistance 9, 10 and also responsible for disease recurrence. 11 CD133, CD44 and Ep-CAM have been shown to be specific for CSC cells in CRC and Ep-CAM high / CD44 + positivity has been reported to be associated with metastasis in CRC. 12, 13 CD133 has been shown to be an independent prognostic marker for lower survival rate in CRC patients. 15 However, there are hardly any studies evaluating CSCs-associated molecular signatures in surgical margins and their role in CRC prognosis.
CRC distal margin remains as the least resolved entity in regard to its molecular signatures and prognostic values. Our study explored distal surgical margin conjointly with tumour using established molecular markers specific for CSCs in CRC patients undergoing curative surgical resection.
| MATERIAL AND ME THODS

| Patients and samples
Biopsies were collected from CRC patients undergoing curative surgery between 2013 and 2017 at the Regional Cancer Centre, Trivandrum after human ethics committee approval and sanction from Institutional Review Board. All patients gave written informed consent in accordance with the Declaration of Helsinki. Patient's details and clinical information were collected from medical records of the same institution. In this study, only adenocarcinoma was included, excluding patients exhibiting gastrointestinal tumours.
Patient's demographic details are given in Table S1 . Briefly, patients presented with rectal cancer had undergone a long course of radiotherapy of 50 Gy in 25 fractions followed by low anterior resection and abdominoperineal resection for upper and lower rectal cancer respectively. On the other hand, colon cancer patients went through hemicolectomy. Surgery involved removal of tumour, lymphnodes and associated margins followed by anastomosis for retaining the intestinal continuity.
The biopsies were collected from normal, tumour and distal resection margins from each patient. Biopsies were collected in HBSS (Invitrogen, USA) or in RNA stabilizing buffer (Ambion, Invitrogen, USA) immediately after surgery and transported under cold condition to the laboratory.
| Tissue digestion and cell isolation
CRC tissues were collected after surgery in cold HBSS (Invitrogen, USA) with 2% FBS (Gibco, Invitrogen, USA) in ice and were minced into small pieces using scissors and scalpel. The minced tissues were transferred into 50 ml tube with 10 mL of DMEM media and kept at 37°C in temperature-controlled shaker with mild agitation for 4 hours. After that, DMEM media containing cell suspension was passed through 40 µm cell strainer (BD Bioscience, USA) and pelleted at 1600 g for 5 minutes at 4°C. RBCs were lysed by incubating cell pellet in RBC lysis solution for 5 minutes at room temperature. Cell suspension was centrifuged at 1600 g for 5 minutes at 4°C
and supernatant was discarded. Finally, cell pellet was suspended in DMEM media supplemented with 10% serum and kept at 37°C for 3 hours for recovery.
| Magnetic assorted cell depletion
Lymphocytes were depleted from isolated cells using CD45 Dynabeads (Invitrogen, USA), according to the manufacturer's protocol. Briefly, Dynabeads were added to cell suspension in PBS and incubated at 4°C for 30 minutes in rotary mixing. After incubation, cells with beads were placed on a magnet for 2 minutes and bound cells were discarded. Finally, supernatant was used for further analysis.
| Immunophenotyping
Cell suspension obtained after CD45 depletion was then washed three times with HBSS buffer and pelleted by centrifugation at 1600 g for 5 minutes. Washed cells were suspended in 1 mL HBSS and 1 × 10 6 cells were used for antibody staining according to the manufacturer's protocol. The details of antibodies used are provided in Table S3 . After antibody staining, cells were again washed with ice-cold HBSS and resuspended in HBSS containing 2% FBS.
Cells were kept on ice till flow cytometry analysis was carried out.
Flow Cytometry analysis was carried out using BD FACS ARIA II (BD Bioscience, USA).
| RNA extraction
Total RNA was isolated from approximately 50 mg tissues (normal, tumour and distal margin) by using Trizol reagent (Invitrogen, USA) following the manufacturer's protocol. Isolated RNA quality and quantification were assessed using gel electrophoresis and Nanodrop 1000 (ThermoScientific, USA).
| mRNA sequencing and identification of mutations
Isolated RNA from normal, tumour and distal tissues collected from a CRC patient was quality checked using bioanalyzer. Whole mRNA sequencing was performed with Illumina Nextseq500 (Genotypic Technology, Bangalore, India). The NextSeq500 paired-end raw reads were quality checked using FastQC. NextSeq 500 raw reads were processed by in-house script for adapters and low-quality bases trimming towards 3'-end. 
| Quantitative real-time-PCR
A total of 1 µg of isolated RNA was converted to cDNA from each RNA sample using PrimerScriptcDNA conversion kit (TAKARA, Japan), according to the manufacturer's protocol. Quantitative realtime PCR was performed with SYBR-Green (TAKARA, Japan) based on fluorescence detection method and HT9700 detection system (AB, Life Technologies, USA). Target genes specific primers were designed using NCBI-Primer blast tool for an amplicon size of maximum 150 bp. Analysed genes and the primers used are shown in Table   S2 . PCR was performed in a final volume of 5 µL containing SYBRGreen PCR master mix, 50 ng of cDNA as template and forward and reverse primers. Relative changes in mRNA expression were obtained using ΔΔCt method keeping normal as reference sample and L19 as endogenous control using Data Assist software (AB Life Technologies, USA).
| Immunohistochemistry
The tissues received after surgery were fixed with 4% paraformaldehyde (Sigma-Aldrich, USA) for 16 hours at 4°C and processed with xylene and alcohol gradient followed by embedding with paraffin to make paraffin blocks. Five-micrometre thick sections were mounted on poly L-lysine-coated StarFrost glass slides (Leica, Germany). The sections were deparaffinised in xylene and rehydrated with alcohol 
| Patient stratification
On the basis of expression levels, patients enriched for CSC markers were grouped in four categories: CD133 (Tumor), CD44 (Tumor), CD133 (Distal) and CD44 (Distal). The enrichment was decided by comparing the expression of both markers to the median value of corresponding normal tissue samples.
| Statistical analysis
All statistical analyses in this study were performed using GraphPad Prism 5 and SPSS version 25. For flow cytometry and immunohistochemistry data, we used un-paired t test for mean comparison and Pvalue determination between normal, tumour and distal tissues. For real-time PCR data, one sample t test was performed to determine the P-value comparing log 2 fold change among tumour and distal samples. Kaplan-Meier plots were used to determine the diseasefree survival (DFS) in followed up patients and P-value was obtained
by Gehan-Breslow-Wilcoxon test. Binary logistic regression model was used for multivariate analysis and Hosmer and Lemeshow statistical test was used to derive the P-value and ODDS ratio.
| RE SULTS
| Enrichment of CD133 and CD44 positive cells in colorectal tumour and distal margin
CD133 and CD44 antigens happen to be the most widely studied
CSCs markers in CRC and combination of these markers could be helpful in identifying CSCs. 18 In this study, we investigated CRC patients for cellular expression of CD133 and CD44 antigen using We further analysed for mRNA levels of CD133, CD44, OCT4, SOX2 and BMI1, in tumour and distal margin tissues compared to the matched normal tissues expression using real-time PCR ( Figure   S2 ). mRNA levels did not show any significant expression for the above-mentioned genes unlike protein expression. However, few cases showed enrichment of CD133 and CD44 expression in distal margin tissues as well and CD44 showed a significantly enriched expression in tumours (Log 2 FC of 1.09, P = 0.0044) ( Figure S2B ).
| Enriched CD133 expression in distal margin associated with a higher recurrence rate and lower DFS in CRC patients
To investigate the clinical significance of the enrichment of CD133 and CD44 markers in CRC and distal margin tissues, all the patients quantified for CD133 and CD44 expression were followed-up to a period of 24 months from the day of tumour excision. From follow-up data, we observed that among all the enriched groups, CD133 (Distal) patients showed a significantly higher recurrence rate of 50% (Table 1) . To delineate the DFS in the above-mentioned groups of patients, we used KaplanMeier plot. CD133 (Distal) and CD44 (Distal) showed an early recurrence with first event occurring at 9 months compared to 15 months in negative groups without any effect on overall DFS ( Figure 4C,D) . However, no significant difference in DFS was found among CD133 (Tumour), CD44 (Tumour) and CD44 (Distal) groups compared to control group ( Figure 4A ,B,D). Interestingly, patients enriched for CD133 in distal margin showed significantly lower DFS of 50% compared to CD133 control group with 82% (P = 0.02, HR = 0.18)( Figure 4C ). This is significantly lower than other enriched groups with a DFS of more than 70%.
Further, multivariate analysis results also supported the relation between high expression of CD133 in distal margin with disease recurrence with a ODDS ratio of 15.30 and P = 0.03 ( Table 2) .
However, we could not find any significant association of recurrence with status of tumour stage, lymphnode and distal margin resection length (Table 2) . These results clearly suggest that CD133 expression in distal margin could have crucial role in disease recurrence in CRC.
| D ISCUSS I ON
In Previous reports suggest a relation between local recurrence and survival with resection margin status. 22, 23 In some cases of patients treated with pre-chemoradiotherapy, tumours and margins may not depict any residual cells (also known as minimal residual cancer) during pathological examination; however, these undetectable tumour cells or clusters could possibly be identified using molecular markers. A recent study in breast cancer has shown that the residual cells that persisted after chemoradiotherapy were found to be enriched in CSCs. 24 As CSCs are thought to be the most nasty cells in a tumour, there is a possibility of their escape upon chemoradiotherapy and manifesting minimal residual disease. 25 Recent reports have shown that CD133 marker could be a crucial prognostic factor as higher expression of CD133 was found to be associated with poor clinical outcomes in CRC. 26 Another study has revealed an association between loco-regional recurrence and expression of CD133 and CD44 CSC markers in rectal cancer suggesting their importance in disease prognosis. 27 However, molecular studies on margins associated with CRC are lacking; hence we studied the tumour and its associated distal margin for identification and quantification of putative CSC markers and regulatory genes. Interestingly, the enrichment of CD133 and CD44 positive cells
were not evident in all cases of patients sample analysed (Table S4) A recent study has reported that the expression of CSC markers after preoperative chemoradiotherapy has independent role in predicting recurrence-free survival in rectal patients. 34 Yet, most importantly the question which needs to be addressed happens to be the causal reason behind this heterogeneity in CSC abundance in tumour and distal margin upon therapy and their role in disease prognosis.
To explore the mechanism of CSCs enrichment in pathologically negative distal margin, we performed RNA sequencing of tumour and distal tissue keeping normal tissue as reference. This study revealed a significant number of cancer-associated genes, which were found to be mutated in both tumour and distal margins ( Figure 3A-D) . CD133 and CD44 in CRC. 35, 36 Oct4 and β-catenin are the two major Wnt pathway genes which are involved in stem cell maintenances. 37 In our IHC studies, we observed an increased expression of Oct4 and β-catenin in tumour and distal margins, whereas normal tissues showed minimal expression ( Figure 3G ). Higher Oct4 and β-catenin expression thus again supports the enrichment of CSC in tumour and distal margin tissues. In addition to that, these observation implies that the active involvement of Wnt signalling could be the possible driver behind the enrichment of CD133 and CD44 markers. The expression of CD133 in CRC has already been reported to be involved with drug resistance and disease recurrence and also associated with lower patients survival. 15, 32, 33, 38 However, our follow-up study showed higher recurrence rate in group with CD133 enrichment in distal margin compared to CD133 tumourenriched (Table 1) . Surprisingly, 50% patients enriched for CD133 in distal margin recurred, whereas rest of the groups showed recurrence rate of less than 30% (Table 1 (Table 2) . Interestingly, low distal resection length also did not show any significant relation with recurrence. However, higher expression of CD133 in distal margin found to have significant association with recurrence (P = 0.03), but CD44 expression did not show similar result (P = 0.82) ( Table 2 ). Altogether these results advocate the potential of CD133 marker in CRC prognosis.
We further propose that CD133 expression in distal margin should be evaluated in a larger cohort of sample to validate its potential role as an independent prognostic marker in CRC.
As distal resection margin length remains a crucial parameter in cases of rectal cancer due to challenges associated with sphincter preserving surgery, 20,41 our study suggests molecular evaluation of distal margins along with histopathology for better prognostication of patients with CRC.
| CON CLUS ION
In conclusion, our study for the first time showed that in CRC, distal margin harbouring cells with CSCs characteristics can affect the patient's prognosis. In addition, enrichment of CD133 and CD44 in distal margin are independent of its pathological status.
Although we accept the limitation in our study, for lacking a larger cohort, we further propose that CD133 expression status in distal margin could be a crucial factor in disease progression in CRC patients and could be used as a prognostic marker. As residual cells could be the sole cause behind local recurrence and metastasis, and histological analysis alone may not provide adequate information regarding the heterogeneity of tumour cell types present or molecular alternation set in the tumour and its margins. Based on these observations, we propose that molecular assessment of margin in CRC could be an added tool supplementing histopathology for better treatment and management of CRC patients in the long run. 
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